Evaluation of Platelet Indices and Inflammation Markers in Preeclampsia

Betül Tokgöz Çakır1, Gizem Aktemur1, Gülşan Karabay1

  • 1Department of Perinatology, Ankara Etlik City Hospital, Ankara 06170, Türkiye.

PubMed

Insights

Platelet indices like platelet distribution width (PDW) can help predict adverse neonatal outcomes in preeclampsia. Lower platelet count (PC) and platelet-to-lymphocyte ratio (PLR) are observed in severe preeclampsia cases.

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Neonatology

Background:

  • Preeclampsia is a severe pregnancy complication linked to platelet dysfunction and inflammation.
  • Understanding these factors is crucial for managing preeclampsia and its impact on newborns.

Purpose of the Study:

  • To examine the role of platelet indices and inflammatory markers in preeclampsia.
  • To assess their predictive value for adverse neonatal outcomes.

Main Methods:

  • Compared platelet indices (PC, PDW, MPV, P-LCR) and inflammatory markers (NLR, MLR, PLR, MPVLR) in 118 preeclampsia patients and 118 controls.
  • Analyzed blood samples at the time of diagnosis.

Main Results:

  • Severe preeclampsia showed lower platelet count (PC) and platelet-to-lymphocyte ratio (PLR).
  • Both mild and severe preeclampsia groups had higher platelet distribution width (PDW) than controls.
  • PDW > 13.15 significantly predicted adverse neonatal outcomes (AUC: 0.633).

Conclusions:

  • Platelet count (PC) and platelet-to-lymphocyte ratio (PLR) are reduced in severe preeclampsia.
  • Platelet distribution width (PDW) shows potential as a predictive marker for adverse neonatal outcomes in preeclampsia.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
40
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
446
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.5K